Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 2/20 | 0.43 |
| ▸ | MTTP | P55157 | 11/20 | 0.43 |
| ▸ | APOB | P04114 | 6/20 | 0.43 |
| ▸ | UGCG | Q16739 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
| ▸ | GPR183 | P32249 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6503236 | 0.92 | MAPT (0.39) | SMOMTTPAPOBKDM4EOPRL1 | |
| SCHEMBL7201300 | 0.91 | TRPV4 (0.41) | OPRL1 | |
| SCHEMBL6795217 | 0.85 | SMO (0.47) | SMOMTTPAPOBUGCGGAA | |
| SCHEMBL6647807 | 0.82 | MTTP (0.42) | SMOMTTPAPOBGAASMN1; SMN2 | |
| SCHEMBL6789084 | 0.81 | SMO (0.48) | SMOMTTPAPOBUGCGGAA | |
| SCHEMBL6795238 | 0.81 | SMO (0.47) | SMOMTTPAPOBUGCGGAA | |
| Hydrochloric Acid SCHEMBL6801596 | 0.80 | SMO (0.47) | SMOMTTPAPOBUGCGGAA | |
| SCHEMBL6793327 | 0.79 | SMO (0.59) | SMOMTTPAPOBGAAPOLB | |
| SCHEMBL6499727 | 0.78 | OPRL1 (0.43) | SMOMTTPAPOBOPRL1POLB | |
| SCHEMBL6648554 | 0.78 | GAA (0.45) | SMOMTTPAPOBGAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-25 | — | — | US | disclosed |
| EP-1326835-A1 | BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-07-16 | — | — | EP | disclosed |
| WO-2002028835-A1 | BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | APOB, APOL1, SCARB1 | SMO 2094/4885MTTP 363/4885APOB 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.